Entera Bio (NASDAQ:ENTX) Shares Gap Down – What’s Next?

Entera Bio Ltd. (NASDAQ:ENTX)’s share price gapped down prior to trading on Tuesday. The stock had previously closed at $2.94, but opened at $2.79. Entera Bio shares last traded at $3.1070, with a volume of 38,567 shares.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Guggenheim began coverage on shares of Entera Bio in a research report on Thursday, September 24th. They issued a “buy” rating and a $11.00 price target for the company. Cantor Fitzgerald assumed coverage on Entera Bio in a research report on Tuesday, September 22nd. They set an “overweight” rating on the stock. Wall Street Zen upgraded Entera Bio to a “sell” rating in a research note on Saturday, August 8th. Leerink Partners started coverage on Entera Bio in a research note on Friday, September 18th. They set an “outperform” rating and a $9.00 price objective on the stock. Finally, UBS Group set a $9.00 target price on Entera Bio in a research report on Friday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Entera Bio has a consensus rating of “Moderate Buy” and a consensus target price of $9.60.

Entera Bio Stock Performance

The firm has a market cap of $548.72 million, a price-to-earnings ratio of -9.01 and a beta of 1.40. The business has a fifty day simple moving average of $2.88 and a 200-day simple moving average of $2.04.

Entera Bio (NASDAQ:ENTX) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06). On average, equities analysts anticipate that Entera Bio Ltd. will post -0.40 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Entera Bio stock. Renaissance Technologies LLC increased its holdings in shares of Entera Bio Ltd. (NASDAQ:ENTX) by 338.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 473,442 shares of the company’s stock after buying an additional 365,441 shares during the period. Renaissance Technologies LLC owned about 0.96% of Entera Bio worth $526,000 at the end of the most recent quarter. 14.11% of the stock is owned by institutional investors and hedge funds.

About Entera Bio

Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing orally delivered biologic medicines. The company’s proprietary platform is designed to enable the oral administration of large-molecule therapies, including peptides and proteins that are traditionally delivered by injection.

Entera Bio’s pipeline has included EB613, an oral formulation of parathyroid hormone fragment (teriparatide) being developed for the treatment of osteoporosis, and EB612, an oral parathyroid hormone product intended for hypoparathyroidism.